Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter results were ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.

Teva stock bumped into its 200-day line Wednesday after the drugmaker beat first-quarter profit expectations and raised its earnings outlook for the year. For the year, Teva Pharmaceutical now expects ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stock is trading higher on Wednesday after the company’s first-quarter 2025 financial results. Here are the details. Teva reported revenue of $3.89 ...

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive 44 week data from the RELIEVE UCCD study for duvakitug in ulcerative colitis and Crohn's disease. The investigational monoclonal ...

Teva reported Q1 adjusted earnings per share (EPS) of $0.52, solidly beating Wall Street's target of $0.48. The company missed on sales, however, reporting $3.89 billion for the quarter when $4 ...

The fund increased its Teva stake, which now accounts for 7.51% of 13F AUM and ranks as its 4th-largest holding. Top holdings after the filing: NYSE:CVS: $617.96 million (13.8% of AUM) NYSE:THC: ...

Most companies have a simple story to tell, and generic drug maker Teva Pharmaceutical (NYSE: TEVA) is no different. However, under the simple story is almost always a more complex tale that you need ...